ProKidney Corp. (NASDAQ: PROK) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
1.91
+0.11+6.11%
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | - | Shs Outstand | 148.17M | Perf Week | 6.11% |
| Market Cap | 642.24M | Forward P/E | - | EPS next Y | -0.66 | Insider Trans | -0.24% | Shs Float | 108.81M | Perf Month | 29.05% |
| Enterprise Value | 570.90M | PEG | 3.80 | EPS next Q | -0.12 | Inst Own | - | Short Float | 19.06% | Perf Quarter | 4.37% |
| Income | -156.26M | P/S | - | EPS this Y | - | Inst Trans | - | Short Ratio | 16.75 | Perf Half Y | -2.05% |
| Sales | 818.00K | P/B | - | EPS next Y | -0.90% | ROA | -34.82% | Short Interest | 20.74M | Perf YTD | -14.73% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | 8.83% | 52W High | 3.48 -45.11% | Perf Year | -24.51% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -68.08% | 52W Low | 1.30 46.92% | Perf 3Y | -73.51% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | -252.57% | Volatility | 6.33% 6.70% | Perf 5Y | -80.49% |
| Dividend TTM | - | EV/Sales | - | EPS Y/Y TTM | 11.29% | Oper. Margin | -21664.55% | ATR (14) | 0.12 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 8.36 | Sales Y/Y TTM | - | Profit Margin | -10599.76% | RSI (14) | 58.62 | Recom | 2.38 |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.36 | EPS Q/Q | -15.38% | SMA20 | 4.63% | Beta | 1.83 | Target Price | 4.67 |
| Payout | 0.00% | Debt/Eq | - | Sales Q/Q | - | SMA50 | 14.99% | Rel Volume | 6.58 | Prev Close | 1.80 |
| Employees | 231 | LT Debt/Eq | 0.01 | Earnings | Nov 09 | SMA200 | -1.14% | Avg Volume | 1.44M | Price | 1.91 |
| IPO Date | Jun 30, 2021 | Option/Short | No / Yes | EPS/Sales Surpr. | -7.14% -19.46% | Net Debt/EBITDA | 0.44 | Volume | 9,449,349 | Change | 6.11% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jun-30-25 | Downgrade | B of A Securities | Neutral → Underperform | |
| Sep-04-24 | Reiterated | Bank of America Securities | $4.00 → $3.00 | |
| Sep-03-24 | Reiterated | BTIG | $6.00 → $5.00 | |
| Jun-10-24 | Reiterated | Jefferies | Buy | $6.00 |
| May-28-24 | Reiterated | BTIG | $6.00 | |
| Jan-02-24 | Downgrade | B of A Securities | Buy → Neutral | |
| Dec-21-22 | Reiterated | Jefferies | Buy |
Latest News· Times ET
Sep-11-26
Aug-27-26
Aug-14-26
Aug-14-2611:36AM
Aug-10-26
12:25PM
Jun-30-26
Jun-30-2606:01AM
Company
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1 | 0 | 0 | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | — | — | — | — | |
| Gross Profit | 1 | 0 | 0 | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 52 | 56 | 45 | — | — | — | — | |
| Research and Development | 114 | 128 | 107 | — | — | — | — | |
| Other Operating Expense | 0 | 0 | 0 | — | — | — | — | |
| Operating Income | -165 | -184 | -152 | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 14 | 20 | 22 | — | — | — | — | |
| Net Income Before Taxes | -151 | -164 | -129 | — | — | — | — | |
| Income Taxes | 0 | -1 | 6 | — | — | — | — | |
| Consolidated Net Income | -69 | -61 | -35 | — | — | — | — | |
| Net Income From Continuing Operations | -152 | -163 | -135 | — | — | — | — | |
| Net Income | -69 | -61 | -35 | — | — | — | — | |
| EPS (Recurring) | -0.52 | -0.62 | -0.57 | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.52 | -0.62 | -0.57 | — | — | — | — | |
| EPS (Diluted) | -0.52 | -0.62 | -0.57 | — | — | — | — | |
| EBITDA | -145 | -158 | -126 | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 300.16 | — | — | — | — | — | — | |
| Gross Margin | 100.00 | — | — | — | — | — | — | |
| Operating Margin | -16,500.00 | — | — | — | — | — | — | |
| Net Margin | -6,900.00 | — | — | — | — | — | — | |
| Shares Outstanding | 134 | 98 | 62 | — | — | — | — | |
| Market Capitalization | 300 | 166 | 110 | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Pereira Brian JG | Director | Aug 20 '26 | Sale | 1.42 | 27,052 | 38,411 | 0 | Aug 20 |
| Pereira Brian JG | Director | Aug 19 '26 | Sale | 1.44 | 250,000 | 360,175 | 27,052 | Aug 20 |
| Pereira Brian JG | Director | Aug 18 '26 | Sale | 1.37 | 257,164 | 352,623 | 54,103 | Aug 20 |
| Pereira Brian JG | Director | Nov 13 '25 | Sale | 2.37 | 54,333 | 128,769 | 0 | Nov 14 |
| Pereira Brian JG | Director | Nov 12 '25 | Sale | 2.72 | 255,026 | 694,515 | 54,333 | Nov 14 |
| Weber Darin J. | Chief Regulatory Officer | Jul 08 '25 | Sale | 3.02 | 103,480 | 312,510 | 0 | Jul 09 |
| Control Empresarial de Capitales S.A. de C.V. | 10 percent owner, other: Add'l Rep. Persons-see Ex.99-1 | Apr 22 '25 | Buy | 0.71 | 387,393 | 276,366 | 73,842,723 | Apr 24 |
| Control Empresarial de Capitales S.A. de C.V. | 10 percent owner, other: Add'l Rep. Persons-see Ex.99-1 | Apr 17 '25 | Buy | 0.75 | 25,000 | 18,690 | 73,455,330 | Apr 21 |
| Control Empresarial de Capitales S.A. de C.V. | 10 percent owner, other: Add'l Rep. Persons-see Ex.99-1 | Apr 16 '25 | Buy | 0.75 | 100,000 | 74,820 | 73,430,330 | Apr 18 |
| Control Empresarial de Capitales S.A. de C.V. | 10 percent owner, other: Add'l Rep. Persons-see Ex.99-1 | Apr 15 '25 | Buy | 0.70 | 468,000 | 326,009 | 73,330,330 | Apr 16 |
| Control Empresarial de Capitales S.A. de C.V. | 10 percent owner, other: Add'l Rep. Persons-see Ex.99-1 | Apr 14 '25 | Buy | 0.73 | 268,105 | 194,591 | 72,862,330 | Apr 16 |
| Control Empresarial de Capitales S.A. de C.V. | 10 percent owner, other: Add'l Rep. Persons-see Ex.99-1 | Apr 11 '25 | Buy | 0.61 | 1,900 | 1,155 | 72,594,225 | Apr 14 |
| Control Empresarial de Capitales S.A. de C.V. | 10 percent owner, other: Add'l Rep. Persons-see Ex.99-1 | Apr 10 '25 | Buy | 0.61 | 1,032,218 | 627,692 | 72,592,325 | Apr 14 |
| Weber Darin J. | Chief Regulatory Officer | Sep 19 '24 | Sale | 2.50 | 16,412 | 41,030 | 103,480 | Sep 20 |
| Weber Darin J. | Chief Regulatory Officer | Jul 26 '24 | Sale | 2.50 | 826 | 2,065 | 119,892 | Jul 29 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.